老虎资讯综合08-01
据外媒，在特朗普政府计划进行的一项为期五年的试验中，一些参加医疗保险和医疗补助计划的美国肥胖患者可能会获得昂贵的减肥药物。
医疗保险和医疗补助服务中心的文件显示，根据拟议的计划，州医疗补助计划和医疗保险D部分保险计划将能够自愿选择将Ozempic， Wegovy， Mounjaro和Zepbound纳入患者的“体重管理”目的。这是一个强烈的信号，表明政府将通过政府保险计划更广泛地覆盖GLP-1药物。
根据文件，该试验预计将于2026年4月开始，适用于医疗补助计划，2027年1月适用于医疗保险计划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
